This article is more than 5 years old. Information may no longer be current.
Biosimilar to rituximab approved in Europe
Rixathon, a biosimilar to rituximab and manufactured by Sandoz, was approved in Europe for rheumatoid arthritis, granulomatosis with polyangiitis, microscopic polyangiitis, non-Hodgkin’s lymphoma and chronic lymphocytic leukemia, according to a company press release.
“Today’s approval of Rixathon represents a big win for patients in Europe with blood cancers and immunological diseases because it enables increased access to biologics,” Carol Lynch, global head of biopharmaceuticals at Sandoz, said in the release. “It also allows health care systems to redeploy resources to other areas of high need, particularly innovative therapies.”
She added, “Sandoz is committed to increasing patient access to biologic medicines, and Rixathon will be one of the five major launches we plan in the next 4 years. We have worked with care and passion toward this approval, and now is the time when we are bringing this medicine to health care professionals and patients in Europe.”
Reference: